Yipinhong Pharmaceutical Co Ltd Class A - Asset Resilience Ratio

Latest as of June 2026: 1.01%

Yipinhong Pharmaceutical Co Ltd Class A (300723) has an Asset Resilience Ratio of 1.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Yipinhong Pharmaceutical Co Ltd Class A current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥45.33 Million
≈ $6.63 Million USD Cash + Short-term Investments

Total Assets

CN¥4.49 Billion
≈ $656.73 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Yipinhong Pharmaceutical Co Ltd Class A's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 300723 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥45.33 Million 1.01%
Total Liquid Assets CN¥45.33 Million 1.01%

Asset Resilience Insights

  • Limited Liquidity: Yipinhong Pharmaceutical Co Ltd Class A maintains only 1.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Yipinhong Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio

Compare Yipinhong Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Yipinhong Pharmaceutical Co Ltd Class A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Yipinhong Pharmaceutical Co Ltd Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.11% CN¥4.75 Million
≈ $694.52K
CN¥4.40 Billion
≈ $644.46 Million
-0.81pp
2023-12-31 0.92% CN¥40.44 Million
≈ $5.92 Million
CN¥4.41 Billion
≈ $644.63 Million
-0.84pp
2022-12-31 1.76% CN¥72.19 Million
≈ $10.56 Million
CN¥4.10 Billion
≈ $599.73 Million
+1.36pp
2021-12-31 0.41% CN¥15.03 Million
≈ $2.20 Million
CN¥3.70 Billion
≈ $542.07 Million
-0.20pp
2020-12-31 0.61% CN¥13.00 Million
≈ $1.90 Million
CN¥2.15 Billion
≈ $313.90 Million
-1.38pp
2019-12-31 1.98% CN¥35.60 Million
≈ $5.21 Million
CN¥1.79 Billion
≈ $262.64 Million
--
pp = percentage points

About Yipinhong Pharmaceutical Co Ltd Class A

SHE:300723 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.23 Billion
CN¥15.25 Billion CNY
Market Cap Rank
#5813 Global
#1098 in China
Share Price
CN¥33.77
Change (1 day)
-0.68%
52-Week Range
CN¥29.56 - CN¥61.82
All Time High
CN¥80.53
About

ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more